The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor α activation of microglia and extends survival of G93A-SOD1 transgenic mice

Journal of Neurochemistry

Volumn 91, Issue 1, 2004, Pages 133-143

  West, Melinda ^a   Mhatre, Molina ^a,b   Ceballos, Alex ^a   Floyd, Robert A ^a,b,c   Grammas, Paula ^a,c   Gabbita, S Prasad ^d   Hamdheydari, Ladan ^c   Mai, Tammy ^a   Mou, Shenyun ^a   Pye, Quentin N ^a   Stewart, Charles ^a   West, Stuart ^a   Williamson, Kelly S ^a   Zemlan, Frank ^d   Hensley, Kenneth ^a,b,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d Phase 2 Discovery Inc   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cytokines; Lipoxygenase; Microglia; Neuroinflammation; Nordihydroguaiaretic acid

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; INFLAMMATION; MALE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; TRANSGENIC MOUSE; UPREGULATION;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BEHAVIOR, ANIMAL; BLOTTING, NORTHERN; BLOTTING, WESTERN; BODY MASS INDEX; CELL LINE; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; LIPOXYGENASE INHIBITORS; MICE; MICE, TRANSGENIC; MICROGLIA; MODELS, NEUROLOGICAL; MOTOR ACTIVITY; NITRIC OXIDE; NORDIHYDROGUAIARETIC ACID; PARALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROTAROD PERFORMANCE TEST; SPINAL CORD; STATISTICS, NONPARAMETRIC; SUPEROXIDE DISMUTASE; SURVIVAL; TAU PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS MUSCULUS;

EID: 4744362369     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02700.x     Document Type: Article

References (58)

1. Allen S., Heath P. R., Kirby J., Wharton S. B., Cookson M. R., Menzies F. M., Banks R. E. and Shaw P. J. (2003) Analysis of the cytosolic proteome in a cell-culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteosome, antioxidant defenses and nitric oxide synthetic pathways. J. Biol. Chem. 278, 6371-6383.
2. Bigby T. D. (2002) The yin and yang of 5-lipoxygenase pathway activation. Mol. Pharmacol. 62, 200-202.
3. Chen M., Onal V. O., Li M. et al. (2000) Minocycline inhibits caspase 1 and caspase 3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801.
4. Cheng A. L., Hsu C. H., Lin J. K. et al. (2002) Phase I clinical trial of curcumin a chemopreventive agent in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895-2900.
5. Colton C. A., Snell J., Chernyshev O. and Gilbert D. L. (1994) Induction of Superoxide anion and nitric oxide production in cultured microglia. Ann. N. Y. Acad. Sci. 738, 54-63.
6. Colville-Nash P. R., Qureshi S. S., Willis D. and Willoughby D. A. (1998) Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor antagonists: correlation with induction of heme oxygenase 1. J. Immunol. 161, 978-984.
7. Cranston E. M., Jensen M. J., Moren A., Brey T., Bell E. T. and Bieter R. N. (1947) The acute and chronic toxicity of nordihydroguaiaretic acid. Fed. Proc. 6, 318-319.
8. Domin J., Higgins T. and Rozengurt E. (1994) Preferential inhibition of platelet derived growth factor-stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid. J. Biol. Chem. 269, 8260-8267.
9. Drachman D. B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S. and Rothstein J. D. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52, 771-778.
10. Dube L. M., Swanson L. J. and Awni W. (1999) Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety. Clin. Rev. Allergy Immunol. 17, 213-222.
11. Elliot J. L. (2001) Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Mol. Brain Res. 95, 172-178.
12. Evan A. P. and Gardner K. D. Jr (1979) Nephron obstruction in nordihydroguaiaretic acid-induced renal cystic disease. Kidney Int. 15, 7-19.
13. Funk C. D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875.
14. Gary D. S., Bruce-Keller A. J., Kindy M. S. and Mattson M. P. (1998) Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J. Cereb. Blood Flow Metab. 18, 1283-1287.
15. Guégan C. and Przedborski S. (2003) Programmed cell death in amyotrophic lateral sclerosis. J. Clin. Invest. 111, 153-161.
16. Gurney M. E., Pu H., Chiu A. Y. et al. (1994) Motor neuron degeneration in mice that express a human Cu Zn superoxide dismutase mutation. Science 264, 1772-1775.
17. Gurney M. E., Cutting F. B., Zhai P., Doble A., Taylor C. P., Andrus P. K. and Hall E. D. (1996) Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39, 147-157.
18. Gurney M. E., Fleck T. J., Himes C. S. and Hall E. D. (1998) Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50, 62-66.
19. Haeggstrom J. Z. and Wetterholm A. (2002) Enzymes and receptors in the leukotriene cascade. Cell. Mol. Life Sci. 59, 742-753.
20. Hall E. D., Oostveen J. A. and Gurney M. (1998) Relationship of microglia and astrocytic activation to disease onset and progression in a transgenic mouse model of familial ALS. Glia 23, 249-256.
21. Hallenbeck J. M. (2002) The many faces of tumor necrosis factor in stroke. Nat. Med. 8, 1363-1368.
22. Helgadottir A., Manolescu A., Thorleifsson G. et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36, 233-239.
23. Hensley K., Floyd R. A., Mou S., Pye Q. N., West M., Williamson K. and Stewart C. (2002) Temporal patterns of cytokine and apoptosis gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82, 365-374.
24. Hensley K., Fedynyshyn J., Ferrel S. et al. (2003) Message and protein level elevations of tumor necrosis factor alpha (TNFα) and TNF-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. 14, 74-80.
25. Kemal C., Louis-Flamberg P., Krupinski-Olsen R. and Shorter A. (1987) Reductive inactivation of soybean lipoxygenase-1 by catechols. Biochemistry 26, 7064-7072.
26. Klivenyi P., Ferrante R. J., Mathews R. T., Bogdanov M. B., Klein A. M., Andreassen O. E., Mueller G., Wermer M., Kaddurah-Daouk R. and Beal M. F. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347-350.
27. Kriz J., Nguyen M. and Julien J. (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10, 268.
28. Kwon H., Park S., Lee S., Lee D.-K. and Yang C.-H. (2001) Determination of binding constant of transcription factor AP-2 and DNA: application of inhibitors. Eur. J. Biochem. 268, 565-572.
29. Lehman A. J., Fitzhugh O. G., Nelson A. A. and Woodard G. (1951) The pharmacological evaluation of antioxidants. Adv. Food Res. 3, 197.
30. Little A. R. and O'Callagha J. P. (2001) Astrogliosis in the adult and developing CNS: is there a role for proinflammatory cytokines? Neurotoxicology 22, 607-618.
31. Madamanchi N. R., Bukoski R. D., Runge M. S. and Rao G. N. (1998) Arachidonic acid activates Jun N-terminal kinase in vascular smooth muscle cells. Oncogene 16, 417-422.
32. Manev H., Uz T., Sugaya K. and Qu T. (2000) Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J. 14, 1464-1469.
33. Marzinzig M., Nussler A. K., Stadler J., Marzinzig E., Barthlen W. P., Nussler N. C., Beger H. G., Morris S. M. Jr and Bruckner U. B. (1997) Improved methods to measure end products of nitric oxide in biological fluids: nitrite, nitrate and S-nitrosothiols. Nitric Oxide Biol. Chem. 1, 177-189.
34. Mathews R. T., Yang L., Browne S., Baik M. and Beal M. F. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl Acad. Sci. USA 95, 8892-8897.
35. McGeer P. L. and McGeer E. G. (2001) Inflammation, autotoxicity, and Alzheimer disease. Neurobiol. Aging 22, 799-809.
36. Nguyen M. D., Julien J.-P. and Rivest S. (2001) Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1β in neurodegeneration. Ann. Neurol. 50, 630-639.
37. Poloni M., Facchetti D., Mai R., Micheli A., Agnoletti L., Francolini G., Mora G., Camana C., Mazzini L. and Bachetti T. (2000) Circulating levels of tumour necrosis factor alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 287, 211-214.
38. Pompl P. N., Ho L., Bianchi M., McManus T., Quin W. and Pasinetti G. M. (2003) A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17, 725-727.
39. Rizzo M. T. and Carlo-Stella C. (1996) Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha induced activation of the c-jun amino-terminal kinase in stromal cells. Blood 88, 3792-3780.
40. Robertson J., Beaulieu J.-M., Doroudchi M. M., Durham H. D., Julien J.-P. and Mushynski W. E. (2001) Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor alpha. J. Cell Biol. 155, 217-226.
41. Salari H., Braquet P. and Borgeat P. (1984) Comparative effects of indomethacin acetylenic acids 15-HETE nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot. Med. 13, 53-60.
42. Schewe C., Schewe T. and Wendel A. (1994) Strong inhibition of mammalian lipoxygenases by the anti-inflammatory seleon-organic compound ebselen in the absence of glutathione. Biochem. Pharmacol. 48, 65-75.
43. Shanahan J. C. and St Clair W. (2002) Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease Clin. Immunol. 103, 231-242.
44. Sheikh N. M., Philen R. M. and Love L. A. (1997) Chaparral-associated hepatotoxicity. Arch. Intern. Med. 157, 913-919.
45. Shishido Y., Furushiro M., Hashimoto S. and Yokokura T. (2001) Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia. Pharmacol. Biochem. Behav. 69, 469-474.
46. Skrzypczak-Jankun E., McCabe N. P., Selman S. H. and Jankun J. (2000) Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence. Int. J. Mol. Med. 6, 521-526.
47. Uz T., Pesold C., Longone P. and Manev H. (1998) Aging associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J. 12, 439-449.
48. Van Den Bosch L., Tilkin P., Lemmens G. and Robberecht W. (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 18, 1067-1070.
49. Walker W. S., Gatewood J., Olivas E., Askew D. and Havenith C. E. G. (1995) Mouse microglial cell lines differing in constitutive and interferon-gamma-inducible antigen-presenting activities for naïve and memory CD4+ and CD8+ T cells. J. Neuroimmunol. 63, 163-174.
50. Werz O., Klemm J., Samuelsson B. and Radmark O. (2000) 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc. Natl Acad. Sci. USA 97, 5261-5266.
51. Whitman S., Gezginci M., Timmermann B. N. and Holman T. R. (2002) Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean 12-human and 15-human lipoxygenase. J. Med. Chem. 45, 2659-2666.
52. 2-linked cascade. J. Biol. Chem. 275, 32357-32362.
53. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H. and Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.
54. Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Niwa J., Takeuchi H., Doyu M. and Sobue G. (2002) Differential expression of inflammation and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 80, 158-167.
55. Zemlan F. P. (1999) Antibodies to CSF Tau: characterization of antibodies recognizing cerebrospinal fluid structural proteins. J. Neurochem. 73, 437-438.
56. Zemlan F. P. and Jauch E. C. (1999) Serum and CSF biomarker of neuronal damage in traumatic brain injury. J. Neurotrauma 16, 690.
57. Zemlan F. P., Rosenberg W. S., Luebbe P. A., Campbell T. A., Dean G. E., Weiner N. E., Cohen J. A., Rudick R. A. and Woo D. (1999) Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J. Neurochem. 72, 741-750.
58. Zhu S., Stavrovskaya I. G., Drozda M. et al. (2002) Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78.